LB Pharmaceuticals Inc
LBRX
$29.66
-$1.75-5.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -66.09% | -222.61% | 30.12% | 4.10% | -4.63% |
| Total Depreciation and Amortization | -3.53% | 4.94% | 4.52% | -1.90% | -1.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.54% | 1,314.07% | 26.75% | 218.94% | -106.06% |
| Change in Net Operating Assets | 29.16% | -9,724.74% | 95.18% | 27.34% | 2.88% |
| Cash from Operations | -28.65% | -436.70% | 50.87% | 15.53% | -43.48% |
| Capital Expenditure | 20.00% | -- | 100.00% | 71.43% | 91.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | -1,893.08% | -50.00% | -63.70% |
| Cash from Investing | 20.00% | 99.91% | -1,897.39% | -49.91% | -63.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -429.74% | 95.18% | -- | -- | -- |
| Cash from Financing | 8,119.74% | -100.39% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 465.09% | -107.56% | 5,945.20% | -38.87% | -139.98% |